Evidence map›Paper›PMID 7544805›Full record

ArticleThe Journal of clinical investigation1995

Regulation of arachidonic acid, eicosanoid, and phospholipase A2 levels in murine mast cells by recombinant stem cell factor.

A N Fonteh, J M Samet, F H Chilton

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Nanoliposomal delivery of cytosolic phospholipase ANanomedicine : nanotechnology, biology, and medicine · 2018
    Article
  3. Article
  4. Pathologic thrombopoiesis of rheumatoid arthritis.Rheumatology international · 2003
    Review
  5. Regulation and metabolism of arachidonic acid.Clinical reviews in allergy & immunology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

A N FontehDepartment of Internal Medicine, Bowman Gray School of Medicine, Winston-Salem, North Carolina 27517, USA.
J M Samet
F H Chilton
Wake Forest University · US

Funding

ARACHIDONIC ACID LIBERATION AND REMODELING IN MAST CELLSR01AI024985 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CHILTON, FLOYD H · 1993 to 1997
–
RELATIONSHIP BETWEEN PLATELET ACTIVATING FACTOR &EICOSAR01AI026771 · NIAID · WAKE FOREST UNIVERSITY · PI CHILTON, FLOYD H · 1988 to 1992
–
BIOCHEMICAL INTERACTIONS BETWEEN LIPID MEDIATOR CLASSESR29AI024985 · NIAID · WAKE FOREST UNIVERSITY · PI CHILTON, FLOYD H · 1988 to 1992
–
NIAID NIH HHS AI 24985NIAID NIH HHS AI 26771
6 · The paper itself

Abstract

The current study evaluates the capacity of recombinant rat stem cell factor (rrSCF) to regulate enzymes that control AA release and eicosanoid generation in mouse bone marrow-derived mast cells (BMMCs). Initial studies indicated that rrSCF provided for 24 h inhibited the release of AA into supernatant fluids of antigen- and ionophore A23187-stimulated BMMCs. Agonist-induced increases in cellular levels of AA were also inhibited, albeit to a lesser degree by rrSCF. To determine the inhibitory mechanism, several steps (e.g., mobilization of cytosolic calcium, release of BMMC granules, and regulation of phospholipase A2 [PLA2] activity) that could influence AA release were measured in rrSCF-treated cells. rrSCF did not alter the capacity of BMMCs to mobilize cytosolic calcium or release histamine in response to antigen and ionophore. BMMCs released large amounts of PLA2 with characteristics of the group II family in response to antigen and ionophore A23187. rrSCF treatment of BMMCs reduced the secretion of this PLA2 activity by BMMCs. Partial purification of acid-extractable PLA2 from rrSCF-treated and untreated BMMCs suggested that rrSCF decreased the quantity of acid-stable PLA2 within the cells. In contrast to group II PLA2, the quantity of cPLA2 (as determined by Western blot analysis) increased in response to rrSCF. To assess the ramifications of rrSCF-induced reductions in AA and group II PLA2, eicosanoid formation was measured in antigen- and ionophore-stimulated BMMCs, rrSCF-inhibited (100 ng/ml, 24 h) prostaglandin D2 (PGD2), thromboxane B2, and leukotriene B4 by 48.4 +/- 7.7%, 61.1 +/- 10.0% AND 38.1 +/- 3.6%, respectively, in antigen-stimulated cells. Similar patterns of inhibition were observed in ionophore-stimulated BMMCs. The addition of a group I PLA2 or exogenous AA to BMMCs reversed the inhibition of eicosanoid generation induced by rrSCF. Together, these data indicate that rrSCF differentially regulates group II and cytosolic PLA2 activities in BMMCs. The resultant reductions in eicosanoid generation suggest that group II PLA2 provides a portion of AA that is used for eicosanoid biosynthesis by BMMCs.

Indexed as

AnimalsArachidonic AcidCalcimycinCalciumCells, CulturedCytosolDose-Response Relationship, DrugEicosanoidsFatty Acids, NonesterifiedHematopoietic Cell Growth FactorsKineticsMast CellsMiceMice, Inbred CBAPhospholipases APhospholipases A2Arachidonic AcidCalcimycinCalciumEicosanoidsFatty Acids, NonesterifiedHematopoietic Cell Growth FactorsPhospholipases APhospholipases A2Recombinant ProteinsStem Cell Factor

Identifiers

PMID7544805
PMCPMC185766
OpenAlexW2094194991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.